Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among…
News
FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on a Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy,…
China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
New $100M Program Aims to Improve Diversity in Clinical Trials
A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity…
Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU
Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and …
Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19
Myeloma UK is calling for more data transparency in government efforts to safeguard myeloma patients during the COVID-19 pandemic. This comes after results…
Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715
ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people…
Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says
SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents…
Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma…
